Literature DB >> 7317106

Binding of maytansinoids to tubulin.

J York, M K Wolpert-DeFilippes, D G Johns, V S Sethi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7317106     DOI： 10.1016/0006-2952(81)90524-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  4 in total

1.  Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.

Authors:  Manu Lopus; Emin Oroudjev; Leslie Wilson; Sharon Wilhelm; Wayne Widdison; Ravi Chari; Mary Ann Jordan
Journal:  Mol Cancer Ther       Date:  2010-10       Impact factor: 6.261

2.  Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.

Authors:  Kathleen R Whiteman; Holly A Johnson; Michele F Mayo; Charlene A Audette; Christina N Carrigan; Alyssa LaBelle; Lawrence Zukerberg; John M Lambert; Robert J Lutz
Journal:  MAbs       Date:  2014-01-08       Impact factor: 5.857

3.  High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.

Authors:  Victor S Goldmacher; Charlene A Audette; Yinghua Guan; Eriene-Heidi Sidhom; Jagesh V Shah; Kathleen R Whiteman; Yelena V Kovtun
Journal:  PLoS One       Date:  2015-02-11       Impact factor: 3.240

4.  Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters.

Authors:  Walid Fayad; Mårten Fryknäs; Slavica Brnjic; Maria Hägg Olofsson; Rolf Larsson; Stig Linder
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.